Adocia Sa · EURONEXT:ADOC

Adocia Sa — Investor Presentation (April 2019)

36 slides from Adocia Sa's investor presentation, April 2019

  1. Slide 1: Corporate Presentation – April 2019

    ADOCIA INNOVATIVE MEDICINE FOR EVERYONE, EVERYWHERE Corporate Presentation – April 2019

  2. Slide 2: Disclaimer

    INTRODUCTION Disclaimer This corporate presentation (the “Presentation”) has been prepared by ADOCIA (the “Company”) and is provided for information purposes only. It is not for promotional use. References herein to the Presentation shall mean and include this document, any oral presentation accompa

  3. Slide 3: ADOCIA in summary

    ADOCIA ADOCIA in summary Business model delivers cost-effective innovation based on already-approved 1 proteins, enhanced with BioChaperone® 2 Key clinical diabetes assets including ultra-rapid insulin BC Lispro, modern premix BC Combo, ADO09 (Pramlintide Insulin) and ready-to-use BC Glucagon 3 $50M

  4. Slide 4: Adocia's management and team

    ADOCIA Adocia’s management and team Gérard Soula Olivier Soula Valérie Rémi Soula Steve Daly PhD, MBA PhD, MBA Danaguezian PhD, MBA President & CEO Deputy General Manager, Chief Financial Officer Director of BD & Legal US General Manager Co-founder Director of R&D Co-founder Co-founder  Focused on

  5. Slide 5: BioChaperone Technology

    BIOCHAPERONE® TECHNOLOGY 5 April 2019

  6. Slide 6: BioChaperone unlocks the potential of proteins and peptides

    ADOCIA BioChaperone® unlocks the potential of proteins and peptides and their combinations in a cost-effective way BioChaperone® Proteins and peptides (insulin, GLP-1 RA, pramlintide, (library of molecules) glucagon, teduglutide…) [BioChaperone® Protein] Complex  Improved solubility Improved stabi

  7. Slide 7: BioChaperone-enabled innovation in diabetes and beyond

    ADOCIA BioChaperone-enabled innovation in diabetes and beyond Diabetes clinical pipeline Preclinical pipeline In vitro PC Phase I/II Phase III In vitro PC Phase I/II BC Lispro U100 Diabetes THDB BC Lispro U200 BC Gla GLP-1 THDB BC Combo Other indications (BC Gla Lis) BC Gluc GLP-1 Obesity HinsBet U1

  8. Slide 8: Recent developments

    KEY DEVELOPMENTS Recent developments BUSINESS PIPELINE  Strategic alliance with Tonghua Dongbao  BC Lispro & BC Combo  April 2018 – 2 Licensing agreements for BC Lispro & BC  Preparation of bridging study with new APIs (lispro Combo in China & other Asian and Middle-East territories - & glargine

  9. Slide 9: Adocia Lead Insulin Programs

    ADOCIA LEAD INSULIN PROGRAMS BIOCHAPERONE® LISPRO & BIOCHAPERONE® COMBO 9 April 2019

  10. Slide 10: People with diabetes require simpler, more physiologic treatments

    MARKET People with diabetes require simpler, more physiologic treatments 425M1 26M 2  Despite 100 years of medical treatment, long-term consequences of diabetes remain a major issue people with on insulin diabetes in 2017  There is a need to address the underlying complexity of diabetes  With mor

  11. Slide 11: BioChaperone Insulin formulations fit the medical need for innovation

    MARKET BioChaperone® Insulin formulations fit the medical need for innovation in the prandial space  BioChaperone® Insulins deliver disruptive innovation for prandial insulin therapy:  Best-in-class injectable products for prandial glycemic control  Potential to be priced competitively (based on

  12. Slide 12: Adocia and Tonghua Dongbao entered strategic alliance

    TONGHUA DONGBAO Adocia and Tonghua Dongbao entered strategic alliance to develop best-in-class insulins  Adocia and Tonghua Dongbao (THDB) strategic alliance:  Licensing agreements for BioChaperone (BC) Lispro & BC Combo  Supply agreements for insulin glargine and insulin lispro  THDB is the loc

  13. Slide 13: Strategic licensing deals with THDB for BC Lispro & BC Combo

    LICENSE Strategic licensing deals with THDB for BC Lispro & BC Combo in Chinese market >100M1  Large and underserved Chinese insulin market features multiple drivers for growth People with diabetes in 65%2  Rapidly growing (CAGR 12%)2, with the number of treated patients set to double in the 30M 3

  14. Slide 14: Strategic supply agreements with THDB open global opportunities

    SUPPLY Strategic supply agreements with THDB open global opportunities for Adocia  With access to stable, high-quality insulin lispro and insulin glargine supply, Adocia now gains full control over BC Lispro and BC Combo development, notably in US, EU and Japan:  Partnering opportunities are multi

  15. Slide 15: BC Lispro: Ultra-rapid insulin with best-in-class potential

    Licensed to THDB in China BC LISPRO Ultra-rapid insulin with best-in-class potential  BioChaperone® Lispro could be a differentiated competitor to Fiasp® (1st approved ultra-rapid insulin, Novo Nordisk). $7B  Consistently faster-on and faster-off metabolic effect vs. Prandial insulin Humalog® & No

  16. Slide 16: Fast-on and fast-off profile is key to close the loop

    BC LISPRO Ultra-rapid insulin with a fast-on and fast-off profile is key element to « close the loop »  Phase 1 trial in closed loop setting was initiated in H1 2019  iLet pump and algorithm (Beta Bionics) Smart CGM Pumps & pens  Dexcom CGM 16 April 2019

  17. Slide 17: Next steps for BC Lispro global development

    BC LISPRO Next steps for BC Lispro global development BC Lispro in China BC Lispro in US/EU/Japan/RoW (THDB) (Adocia)  Targeting Phase 3 start in China in 2019  Bridging study planned in Q3 2019  Undisclosed milestone attached  Comparability study BC Lispro (THDB insulin lispro) vs. BC Lispro (u

  18. Slide 18: BC Combo: A safer, more efficient alternative to premix insulin

    Licensed BC COMBO A safer and more efficient alternative to premix to THDB in China insulin for the treatment of type 2 diabetes $5B  Premix products are easier to use than basal-bolus regimens but present inferior prandial coverage and a higher risk of hypoglycemia Premix insulin market (2016)1 

  19. Slide 19: Next steps for BC Combo global development

    BC COMBO Next steps for BC Combo global development BC Combo in China & related territories BC Combo in US/EU/Japan & premix markets (THDB) (Adocia)  Bridging study in China planned in 2019  Actively seeking partners for US/Europe/Japan and other premix markets  Will enable to use data from previ

  20. Slide 20: Multihormonal Treatments for Diabetes

    MULTIHORMONAL TREATMENTS FOR DIABETES NEXT GENERATION OF CARE FOR BETTER OUTCOMES 20 April 2019

  21. Slide 21: Innovative multi-hormonal approaches for diabetes and obesity

    RATIONALE Innovative multi-hormonal approaches aim to improve diabetes and obesity management Insulin In combination BC Glargine GLP-1 (T2D) ADO09 Pramlintide Insulin (T1D & T2D) GLP-1 Amylin In combination In a dual-chamber pump BC Glucagon GLP-1 BC Glucagon and Insulin (T1D) (Obesity) Glucagon As

  22. Slide 22: Time-sensitive hormonal pattern maintains normo-glycemia

    DIABETES In non-diabetic people, a time-sensitive hormonal pattern maintains normo-glycemia Schematic representation of hormonal pattern1 Insulin Without diabetes With Type 1 diabetes (T1D) Level of secretion Amylin (relative scale) Glucagon GLP-1 GLP-1 Glucagon Insulin Amylin 0 1 2 3 4 5 6 0 1 2 3

  23. Slide 23: ADO09: Next generation of prandial treatment in T1D

    ADO09 Next generation of prandial treatment to improve long- (PRAM INS ) term outcomes in T1D  ADO09 (Pramlintide /A21G Ins combination) aims to 65%3 79%2 deliver exceptionally tight prandial control, based on Of diabetics live clinical use of pramlintide as an adjunct to intensive insulin of US ad

  24. Slide 24: ADO09 first-in-human trial proof of concept in Type 1 diabetes

    ADO09 First-in-human trial demonstrated proof of concept in (PRAM INS ) people with Type 1 diabetes  In a standardized mixed meal test study in 24 people with T1D1, ADO09 (injected at mealtime) showed:  85% decrease of glycemic excursion in the first 2 hours vs. Humalog® (insulin lispro)  Similar

  25. Slide 25: BC Glucagon: ready-to-use aqueous formulation of human glucagon

    BC GLUCAGON A ready-to-use aqueous formulation of human glucagon for acute and chronic use $400M  BioChaperone® Glucagon is a ready-to-use aqueous formulation of human glucagon supporting: Forecasted market in 20251  Rescue treatment of severe hypoglycemia in a ready-to-use autoinjector: current g

  26. Slide 26: Expanding the Portfolio

    EXPANDING THE PORTFOLIO LEVERAGING BIOCHAPERONE®TRACK-RECORD AND VERSATILITY TO ADDRESS NEW THERAPEUTIC TARGETS 26 April 2019

  27. Slide 27: BioChaperone can improve approved or NCE proteins and peptides

    BC PLATFORM BioChaperone® can be used to improve both approved or NCE proteins and peptides BioChaperone® /Protein complex  Leveraging Adocia core competencies in protein and peptide formulation to fit partner’s needs  More than 20 clinical trials (Phase 1-3) to date on 6 different pharmaceutical

  28. Slide 28: Expanding the use of BioChaperone platform

    PIPELINE EXPANSION Expanding the use of BioChaperone® platform  BioChaperone Glucagon GLP-1 for the treatment of obesity  Obesity prevalence has tripled from 1975 to 2016 globally2, triggering the development of 36.5%1 more aggressive treatment regimens: of US adults are obese  Based on BC Glucag

  29. Slide 29: Key financial elements

    ADOCIA Key financial elements Financial summary Shareholders’ equity (December 2018) Analysts  Listed on Euronext Paris (ADOC) Free Float Soula Family 22 %  Kepler Market (Arsène Guekam)  6.9M shares outstanding 59.4%  Oddo (Pierre Corby)  Louis Capital Partners (Pierre  ADR program in the US

  30. Slide 30: Expected News Flow

    ADOCIA Expected News Flow PIPELINE BUSINESS  BC LISPRO  BC LISPRO & BC COMBO  China (THDB): Phase 3 start planned in 2019  Looking to partner in US/EU/Japan/LatAm/Oceania  US/EU/JAP:  Insulin lispro Ph. 1 bridging study planned Q3 2019  ADO09 (PRAMLINTIDE INSULIN) & BC GLUCAGON  Phase 3 fili

  31. Slide 31: Appendix

    APPENDIX 31 April 2019 ADOCIA i

  32. Slide 32: Adocia is supported by a top-tier Medical Advisory Board

    ADOCIA Adocia is supported by a top-tier Medical Advisory Board  Dr. Jay Skyler, MD, Chairman, University of Miami (US)  Dr. Vanita Aroda, MD, MedStar Health Research Institute (US)  Dr. Bruce Bode, MD, Emory University (US)  Dr. John Buse, MD, PhD, University of North Carolina (US)  Dr. Eda Ce

  33. Slide 33: Notes

    Notes 33 April 2019 ADOCIA f-

  34. Slide 34: Notes

    Notes 34 April 2019 ADOCIA f-

  35. Slide 35: Notes

    Notes 35 April 2019 ADOCIA f-

  36. Slide 36: Thank you for your kind interest

    THANK YOU FOR YOUR KIND INTEREST ADOCIA 115 avenue Lacassagne 69003 Lyon – France Tel +33 4 72 610 610 contact@adocia.com 36 April 2019

Adocia — Investor Presentation (April 2019) on 6ix